Heron Therapeutics (NASDAQ:HRTX) PT Set at $50.00 by Cantor Fitzgerald

Cantor Fitzgerald set a $50.00 target price on Heron Therapeutics (NASDAQ:HRTX) in a report published on Tuesday, October 30th. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other analysts also recently issued reports on HRTX. ValuEngine downgraded shares of Heron Therapeutics from a buy rating to a hold rating in a report on Tuesday, September 4th. Zacks Investment Research raised shares of Heron Therapeutics from a hold rating to a buy rating and set a $43.00 price objective for the company in a report on Wednesday, July 18th. Stifel Nicolaus initiated coverage on shares of Heron Therapeutics in a report on Thursday, September 13th. They set a buy rating and a $55.00 price objective for the company. Finally, BidaskClub downgraded shares of Heron Therapeutics from a hold rating to a sell rating in a report on Saturday, September 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the stock. The stock has an average rating of Buy and an average price target of $52.09.

NASDAQ:HRTX traded up $1.40 during trading hours on Tuesday, hitting $24.68. The stock had a trading volume of 1,347,385 shares, compared to its average volume of 1,139,961. Heron Therapeutics has a one year low of $15.00 and a one year high of $42.90. The company has a market cap of $1.82 billion, a price-to-earnings ratio of 6.76 and a beta of 1.45.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.05). Heron Therapeutics had a negative net margin of 326.79% and a negative return on equity of 72.23%. The firm had revenue of $19.79 million during the quarter, compared to the consensus estimate of $19.84 million. During the same period in the previous year, the business earned ($0.77) earnings per share. The firm’s revenue for the quarter was up 130.9% on a year-over-year basis. As a group, sell-side analysts forecast that Heron Therapeutics will post -2.34 earnings per share for the current fiscal year.

In other Heron Therapeutics news, Director Kevin C. Tang sold 2,695,000 shares of the business’s stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $35.75, for a total value of $96,346,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Kimberly Manhard sold 6,000 shares of the business’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $32.07, for a total transaction of $192,420.00. Following the completion of the sale, the vice president now directly owns 6,000 shares of the company’s stock, valued at $192,420. The disclosure for this sale can be found here. Insiders sold 2,701,494 shares of company stock valued at $96,553,796 over the last three months. 16.20% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new position in shares of Heron Therapeutics in the second quarter valued at about $151,000. NewSquare Capital LLC purchased a new position in shares of Heron Therapeutics in the second quarter valued at about $211,000. Jefferies Group LLC purchased a new position in shares of Heron Therapeutics in the third quarter valued at about $202,000. Verition Fund Management LLC purchased a new position in shares of Heron Therapeutics in the third quarter valued at about $208,000. Finally, Pacer Advisors Inc. purchased a new position in shares of Heron Therapeutics in the third quarter valued at about $223,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading: How Do You Calculate Return on Investment (ROI)?

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply